Revance Therapeutics, Inc. (NASDAQ:RVNC) CEO L Daniel Browne sold 22,800 shares of the firm’s stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $22.76, for a total transaction of $518,928.00. Following the transaction, the chief executive officer now directly owns 178,850 shares of the company’s stock, valued at approximately $4,070,626. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Shares of Revance Therapeutics, Inc. (RVNC) traded down 2.15% during midday trading on Friday, hitting $22.80. 77,885 shares of the company traded hands. Revance Therapeutics, Inc. has a 52 week low of $12.35 and a 52 week high of $28.30. The stock’s market capitalization is $702.67 million. The company has a 50-day moving average price of $23.49 and a 200-day moving average price of $22.11.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping the consensus estimate of ($0.93) by $0.03. The business had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.05 million. Revance Therapeutics had a negative net margin of 32,936.67% and a negative return on equity of 55.21%. The company’s revenue was up .0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.88) EPS. Analysts anticipate that Revance Therapeutics, Inc. will post ($3.77) earnings per share for the current fiscal year.

WARNING: “Revance Therapeutics, Inc. (RVNC) CEO L Daniel Browne Sells 22,800 Shares” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/08/26/revance-therapeutics-inc-rvnc-ceo-l-daniel-browne-sells-22800-shares.html.

A number of equities analysts have weighed in on RVNC shares. Aegis reaffirmed a “buy” rating and set a $28.00 target price on shares of Revance Therapeutics in a research note on Monday, May 1st. Zacks Investment Research downgraded shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 9th. ValuEngine raised shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 9th. BidaskClub raised shares of Revance Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Finally, Cantor Fitzgerald started coverage on shares of Revance Therapeutics in a research note on Thursday, July 20th. They set an “overweight” rating and a $50.00 target price for the company. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $34.80.

Several hedge funds have recently modified their holdings of RVNC. Schwab Charles Investment Management Inc. increased its stake in shares of Revance Therapeutics by 4.4% in the first quarter. Schwab Charles Investment Management Inc. now owns 92,490 shares of the biopharmaceutical company’s stock valued at $1,924,000 after buying an additional 3,933 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Revance Therapeutics by 16.4% in the first quarter. Geode Capital Management LLC now owns 178,435 shares of the biopharmaceutical company’s stock valued at $3,711,000 after buying an additional 25,075 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Revance Therapeutics by 5.1% in the first quarter. Vanguard Group Inc. now owns 868,118 shares of the biopharmaceutical company’s stock valued at $18,056,000 after buying an additional 42,466 shares in the last quarter. FMR LLC increased its stake in shares of Revance Therapeutics by 216.9% in the first quarter. FMR LLC now owns 316,900 shares of the biopharmaceutical company’s stock valued at $6,592,000 after buying an additional 216,900 shares in the last quarter. Finally, American International Group Inc. increased its stake in shares of Revance Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 12,590 shares of the biopharmaceutical company’s stock valued at $262,000 after buying an additional 834 shares in the last quarter. Institutional investors and hedge funds own 87.94% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Insider Buying and Selling by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Stock Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related stocks with our FREE daily email newsletter.